In a report released today, Joanne Wuensch from BMO Capital reiterated a Hold rating on Endologix Inc (NASDAQ: ELGX), with a price target of $4. The company’s shares opened today at $3.71.
According to TipRanks.com, Wuensch is a 5-star analyst with an average return of 12.4% and a 72.7% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Baxter International, and Edwards Lifesciences.
The word on The Street in general, suggests a Hold analyst consensus rating for Endologix Inc with a $5.17 average price target, which is a 39.4% upside from current levels. In a report released today, Piper Jaffray also downgraded the stock to Hold.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $6.72 and a one-year low of $2.66. Currently, Endologix Inc has an average volume of 454K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Endologix, Inc. engages in the research, development, manufacture, and trade of medical devices for the treatment of aortic disorders such as abdominal aortic aneurysms (AAA). Its products include AFX Endovascular AAA System, Nellix and Ovation. The company was founded in March 1992 and is headquartered in Irvine, CA.
